Tag Archive for: neurology

Alchemab Therapeutics initiates Phase 1 clinical trial of ATLX-1282 and announces Series A financing extension

/in

Follows successful completion of pre-clinical activities by Alchemab as part of earlier licensing deal with Eli Lilly and Company for ATLX-1282 Financing included participation from Eli Lilly and Company and Ono Venture Investment alongside significant support from world-class existing investors  Cambridge, UK, 9 September 2025 – Alchemab Therapeutics (Alchemab), a biopharmaceutical company which identifies and develops […]

Read more

Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder

/in

Suresnes (France), September 8, 2025 – Servier, an independent international pharmaceutical group governed by a foundation, today announced that it has entered into a definitive agreement with Kaerus Bioscience for the acquisition of KER-0193, a potential treatment for Fragile X syndrome (FXS), the most common genetic cause of autism spectrum disorder (ASD). This acquisition demonstrates Servier’s […]

Read more

Leriglitazone Marketing Authorization Application submitted for treatment of cerebral adrenoleukodystrophy has been validated by European Medicines Agency

/in

Barcelona, Spain and Düsseldorf, Germany – 23 July 2025 – Minoryx Therapeutics, a late-stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders and Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of CNS disorders, today announce that the Marketing Authorization Application (MAA) for Minoryx’s […]

Read more

Neuraxpharm continues international expansion with launch of Neuraxpharm Australia

/in

Avendran Naidu appointed Head of Commercial to lead new affiliate CNS specialist continues growth strategy outside Europe to commercialise CNS treatments, including Nuvigil® (armodafinil), Modavigil® (modafinil), and bring BRIUMVI® (ublituximab) to patients in Australia  Sydney, Australia and Düsseldorf, Germany – 22 July 2025 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on […]

Read more

Neuraxpharm and Dizlin Pharmaceuticals Announce Global Strategic Co-Development Agreement Bringing Next-Generation Drug-Device Therapy to Patients with Advanced Parkinson’s Disease

/in

Infudopa SubC® is a user-friendly and minimally invasive alternative enabling flexible dosing and thereby empowering patients with greater independence Düsseldorf, Germany and Gothenburg, Sweden – 8 July 2025 – Neuraxpharm Group (“Neuraxpharm”), a leading European specialty pharmaceutical company dedicated to central nervous system (CNS) disorders, and Dizlin Pharmaceuticals AB (“Dizlin”), a Swedish R&D company focused […]

Read more
© Optimum Strategic Communications.